Kymera reports early human results for oral IRF5 drug

Kymera ($KYMR) reported results from its first human study of KT-579, an experimental oral medicine targeting the immune regulator IRF5. In healthy volunteers receiving repeated doses, median blood IRF5 reductions reached at least 90% across several dose levels, with similar target reductions in skin. Laboratory testing also showed suppression of inflammatory biomarkers. The company reported no serious or severe adverse events and no adverse events that caused treatment discontinuation.

These findings establish pharmacological activity, rather than clinical benefit in people with autoimmune disease. Kymera plans to begin LUMORA, a randomized, placebo-controlled Phase 1b study, by early 2027. It will evaluate approximately 30 adults with lupus over 16 weeks, primarily examining biomarkers and safety while exploring clinical effects. The program remains investigational, and a short healthy-volunteer study cannot establish long-term safety or treatment effectiveness.

Sources:

• investors.kymeratx.com
• Issuer release or filing via StockTitan